✦ LIBER ✦

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

✍ Scribed by Yamada, Yasuhide; Takahari, Daisuke; Matsumoto, Hiroshi; Baba, Hideo; Nakamura, Masato; Yoshida, Kazuhiro; Yoshida, Motoki; Iwamoto, Shigeyoshi; Shimada, Ken; Komatsu, Yoshito; Sasaki, Yasutsuna; Satoh, Taroh; Takahashi, Keiichi; Mishima, Hideyuki; Muro, Kei; Watanabe, Masahiko; Sakata, Yuh; Morita, Satoshi; Shimada, Yasuhiro; Sugihara, Kenichi

Book ID: 123466188
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 438 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70490-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

S-1 plus oxaliplatin versus capecitabine

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

✍ Yong Sang Hong; Young Suk Park; Ho Yeong Lim; Jeeyun Lee; Tae Won Kim; Kyu-pyo K 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 200 KB

Bevacizumab plus capecitabine versus cap

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

✍ Cunningham, David; Lang, Istvan; Marcuello, Eugenio; Lorusso, Vito; Ocvirk, Janj 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 367 KB

Efficacy and safety of bevacizumab-based

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)

✍ Ducreux, M.; Adenis, A.; Pignon, J.-P.; François, E.; Chauffert, B.; Ichanté, J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 602 KB

Oxaliplatin, fluorouracil, and leucovori

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial

✍ Taieb, Julien; Tabernero, Josep; Mini, Enrico; Subtil, Fabien; Folprecht, Gunnar 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 466 KB

PEAK: A Randomized, Multicenter Phase II

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

✍ Schwartzberg, L. S.; Rivera, F.; Karthaus, M.; Fasola, G.; Canon, J.-L.; Hecht, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 520 KB

A phase II open-label randomized multice

A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer

✍ Lee, Jeeyun; Shin, Sang Joon; Chung, Ik Joo; Kim, Tae Won; Chun, Hoo-Geun; Shin, 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 313 KB